Switching to macitentan in pulmonary arterial hypertension
I. Tsagkaris (Athens, Greece), E. Vrigkou (Athens, Greece), D. Konstantonis (Athens, Greece), F. Frantzeskaki (Athens, Greece), A. Pappas (Athens, Greece), K. Ntaï (Athens, Greece), E. Stagaki (Athens, Greece), A. Armaganidis (Athens, Greece), S. Orfanos (Athens, Greece)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Session: Pulmonary hypertension: therapy
Session type: Thematic Poster
Number: 3045
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Tsagkaris (Athens, Greece), E. Vrigkou (Athens, Greece), D. Konstantonis (Athens, Greece), F. Frantzeskaki (Athens, Greece), A. Pappas (Athens, Greece), K. Ntaï (Athens, Greece), E. Stagaki (Athens, Greece), A. Armaganidis (Athens, Greece), S. Orfanos (Athens, Greece). Switching to macitentan in pulmonary arterial hypertension. 3045
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: